Immatics N.V. (IMTX)

Immatics N.V. (IMTX) Healthcare & Pipeline Overview

Immatics N.V. is a clinical-stage biopharmaceutical company focused on pioneering T cell receptor (TCR)-based immunotherapies for solid tumors. Utilizing adoptive cell therapies (ACT) and TCR Bispecifics, Immatics aims to address unmet needs in cancer treatment, positioning itself within the competitive biotechnology landscape with strategic collaborations.

What Is the Investment Thesis for IMTX?

Immatics N.V. presents a notable research candidate within the biotechnology sector, driven by its innovative TCR-based immunotherapy platform. The company's focus on solid tumors, a challenging area in cancer treatment, positions it to address a significant unmet medical need. Key value drivers include the advancement of its ACTengine and TCR Bispecifics product candidates through clinical trials. The ongoing Phase I trials for IMA201, IMA202, and IMA203 represent near-term catalysts. Strategic collaborations with major pharmaceutical companies like GlaxoSmithKline and Celgene further validate Immatics' technology and provide financial resources. However, the company's negative profit margin of -390.9% highlights the risks associated with clinical-stage biopharmaceutical companies, including the potential for clinical trial failures and regulatory hurdles. Successful clinical outcomes and regulatory approvals are critical for realizing the company's long-term value.

Based on FMP financials and quantitative analysis

IMTX Key Highlights

• Market capitalization of $1.34B reflects investor confidence in Immatics' TCR-based immunotherapy platform.
• Gross margin of 100.0% indicates strong potential profitability upon commercialization of its product candidates.
• Profit margin of -390.9% highlights the significant R&D expenses associated with clinical-stage drug development.
• Beta of 1.34 suggests higher volatility compared to the overall market, typical for biotechnology companies.
• Strategic collaborations with GlaxoSmithKline, MD Anderson Cancer Center, Celgene, and Genmab validate Immatics' technology and provide financial support.

Who Are IMTX's Competitors?

IMTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IMTX's Key Strengths?

• Proprietary TCR discovery platform.
• Clinical-stage pipeline of ACTengine and TCR Bispecifics product candidates.
• Strategic collaborations with major pharmaceutical companies.
• Strong intellectual property portfolio.

What Are IMTX's Weaknesses?

• High R&D expenses and negative profit margin.
• Reliance on clinical trial success and regulatory approvals.
• Limited commercialization experience.
• Competition from established pharmaceutical companies and other biotech firms.

What Could Drive IMTX Stock Higher?

• Data readout from Phase I clinical trials of IMA201, IMA202, and IMA203 expected in late 2026.
• Advancement of TCR Bispecifics program towards clinical development.
• Expansion of strategic collaborations with pharmaceutical companies and academic institutions.
• Regulatory submissions for potential accelerated approval pathways.

What Are the Key Risks for IMTX?

• Negative return on equity (-45.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures or regulatory setbacks could delay or halt the development of product candidates.
• Competition from other immunotherapeutic approaches may limit market share.
• Patent challenges or intellectual property disputes could impact the company's competitive advantage.
• High R&D expenses and negative profit margin require continued access to capital.
• Changes in healthcare regulations or reimbursement policies could affect the commercial viability of Immatics' therapies.

What Are the Growth Opportunities for IMTX?

• Expansion of ACTengine Platform: Immatics has the opportunity to expand its ACTengine platform by developing new TCR-based immunotherapies targeting additional tumor-associated antigens. The global market for adoptive cell therapies is projected to reach $4.9 billion by 2027. By leveraging its expertise in TCR discovery and engineering, Immatics can broaden its pipeline and address a wider range of solid tumors. This expansion is expected to drive long-term growth and increase the company's market share in the immunotherapy space.
• Advancement of TCR Bispecifics Program: Immatics' TCR Bispecifics program represents a significant growth opportunity. These antibody-like molecules offer the potential to redirect T cells to tumor cells, inducing a potent anti-tumor response. The market for bispecific antibodies is rapidly growing, with projections reaching $7.8 billion by 2028. Successful development and commercialization of IMA401 and IMA402 could establish Immatics as a leader in this emerging field.
• Strategic Partnerships and Collaborations: Immatics can further accelerate its growth through strategic partnerships and collaborations with pharmaceutical companies and academic institutions. These collaborations can provide access to new technologies, funding, and clinical trial expertise. The company's existing partnerships with GlaxoSmithKline, MD Anderson Cancer Center, Celgene, and Genmab demonstrate its ability to forge successful alliances. Expanding this network of partnerships will be crucial for driving innovation and commercializing its product candidates.
• Clinical Trial Success and Regulatory Approvals: The successful completion of clinical trials and subsequent regulatory approvals are critical growth drivers for Immatics. Positive data from the ongoing Phase I trials for IMA201, IMA202, and IMA203 could lead to accelerated development and potential market entry. The FDA's accelerated approval pathways for oncology drugs offer opportunities to expedite the regulatory process. Achieving these milestones will significantly enhance the company's value and attract further investment.
• Expansion into New Geographic Markets: While Immatics is headquartered in Germany and primarily focused on the United States, expanding into new geographic markets represents a significant growth opportunity. The European market for cancer therapies is substantial, and emerging markets in Asia and Latin America offer long-term growth potential. Establishing a presence in these markets through partnerships or direct investment could diversify the company's revenue streams and increase its global reach.

What Opportunities Does IMTX Have?

• Expansion of ACTengine platform to target additional tumor-associated antigens.
• Advancement of TCR Bispecifics program and potential market leadership.
• Strategic partnerships and collaborations to accelerate development.
• Expansion into new geographic markets.

What Threats Does IMTX Face?

• Clinical trial failures and regulatory setbacks.
• Competition from other immunotherapeutic approaches.
• Patent challenges and intellectual property disputes.
• Changes in healthcare regulations and reimbursement policies.

What Are IMTX's Competitive Advantages?

• Proprietary TCR Discovery Platform: Immatics possesses a proprietary platform for discovering and engineering T cell receptors (TCRs) that target intracellular tumor antigens. This platform provides a competitive advantage in identifying novel therapeutic targets and developing highly specific immunotherapies.
• Clinical-Stage Pipeline: The company's clinical-stage pipeline of ACTengine and TCR Bispecifics product candidates demonstrates its ability to translate research into tangible therapeutic solutions. This pipeline provides a barrier to entry for competitors and positions Immatics for potential market leadership.
• Strategic Collaborations: Immatics' strategic collaborations with major pharmaceutical companies and academic institutions validate its technology and provide access to resources and expertise. These collaborations enhance the company's credibility and accelerate its development efforts.
• Intellectual Property Portfolio: Immatics has a strong intellectual property portfolio covering its TCR discovery platform, product candidates, and manufacturing processes. This IP protection provides a competitive advantage and prevents competitors from replicating its technology.

What Does IMTX Do?

Immatics N.V., headquartered in Tübingen, Germany, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of T cell receptor (TCR)-based immunotherapies for the treatment of cancer. Founded with the vision of harnessing the power of the immune system to fight cancer, Immatics focuses on developing targeted immunotherapies, primarily for solid tumors. The company employs two distinct treatment modalities: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Immatics' ACTengine product candidates are currently in Phase I clinical trials. These include IMA201, targeting melanoma-associated antigen 4 or 8; IMA202, targeting melanoma-associated antigen 1; and IMA203, targeting preferentially expressed antigen in melanoma. Additionally, IMA204 is in preclinical studies, targeting tumor stroma cells. The company's TCR Bispecifics product candidates, such as IMA401 and IMA402, are in preclinical development for the treatment of solid tumors. Immatics also develops IMA101 for cancer treatment and IMA301, an allogenic cellular therapy product candidate. Immatics has established strategic collaborations with GlaxoSmithKline, MD Anderson Cancer Center, Celgene Switzerland LLC, and Genmab A/S to advance its research and development efforts. These collaborations focus on developing novel adoptive cell therapies and T cell engaging bispecific immunotherapies for various cancer indications. With a focus on innovation and strategic partnerships, Immatics aims to deliver transformative therapies for patients with cancer.

What Products and Services Does IMTX Offer?

• Develops T cell receptor (TCR)-based immunotherapies for cancer treatment.
• Focuses on treating solid tumors through adoptive cell therapies (ACT).
• Creates antibody-like TCR Bispecifics for targeted cancer treatment.
• Conducts Phase I clinical trials for ACTengine product candidates like IMA201, IMA202, and IMA203.
• Develops preclinical TCR Bispecifics product candidates such as IMA401 and IMA402.
• Collaborates with pharmaceutical companies and academic institutions to advance its research and development efforts.
• Aims to deliver transformative therapies for patients with cancer.

How Does IMTX Make Money?

• Develops and out-licenses TCR-based immunotherapies.
• Generates revenue through strategic collaborations and partnerships with pharmaceutical companies.
• Secures funding through venture capital and public offerings to support research and development activities.
• Monetizes its technology through licensing agreements and potential future product sales.

What Industry Does IMTX Operate In?

Immatics N.V. operates within the rapidly evolving biotechnology industry, specifically in the field of cancer immunotherapy. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence. The competitive landscape includes major pharmaceutical companies and specialized biotech firms developing various immunotherapeutic approaches, such as checkpoint inhibitors, CAR-T cell therapies, and TCR-based therapies. Immatics differentiates itself through its focus on TCR-based immunotherapies, which target intracellular tumor antigens, potentially addressing a broader range of solid tumors compared to other approaches. The company's strategic collaborations and clinical-stage pipeline position it to capitalize on the growing demand for innovative cancer treatments.

Who Are IMTX's Key Customers?

• Patients with solid tumors who are candidates for TCR-based immunotherapies.
• Pharmaceutical companies seeking to expand their oncology portfolios through strategic partnerships.
• Academic institutions collaborating on research and development of novel cancer therapies.
• Healthcare providers who prescribe and administer Immatics' therapies.

FY2026 estForward Outlook

Wall Street analysts project Immatics N.V. revenue of about $43.5M for fiscal 2026, with EPS near $-1.95. The estimate reflects 6 contributing analysts.

F-Score 1/9Financial Health

Immatics N.V.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 5.54 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE -45%Key Financial Metrics

Return on equity for Immatics N.V. stands at -45.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -39.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -15.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 8.78 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -17.9%, the inverse of the P/E and a quick read on earnings relative to price.

Immatics N.V. (IMTX) Valuation Context

Valued at $1.34B, IMTX is classified as a small-cap stock. Relative to its peer group, IMTX's quantitative score of 58/100 is below the peer average of 72/100.

Company Profile

Immatics N.V. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tübingen, DE. The company is led by CEO Harpreet Singh. IMTX has traded publicly since 2018.

IMTX Financials

IMTX Latest News

IMTX Analyst Consensus

IMTX MoonshotScore

Latest Immatics N.V. Analysis

IMTX Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources